January   | View Newsletter

February    | View Newsletter

March   | View Newsletter

Includes:

• Us TOO Board Leadership Changes

• MRI Can Identify Metastatic Lymph Nodes

• Treatment Found for Lethal Prostate Cancer

• Index of Articles in the 2011 HotSheets

• 2011 Prostate Cancer Business Leadership Council Members & Supporters Recognized

• Doc Moyad’s “No Bogus Science” Column – “Another Reason to Donate to Us TOO”

• Characteristics & Outcomes of Prostate Cancers Diagnosed by 21-Core Biopsies

• Revlimid® Fails to Help Prostate Cancer

• Ask Doctor Snuffy Myers

• MRI Highly Accurate in Guiding Biopsies

• Read more..

Includes:

• Outercourse Vs. Intercourse Revisited

• Statins & Risk of Fatal Prostate Cancer

• ‘Amazing’ Prostate Cancer Marker (EPCA-2) Paper Now Retracted

• MRI-Guided Prostate Biopsies in Men with Increased PSA & Prior Negative Biopsies

• Docetaxel with/without Estramustine

• Ask Doctor Snuffy Myers

• Proton Therapy Effective for Prostate Cancer

• Recent Additions to the Us TOO Website

• Robot prostatectomy vs. standard surgery

• Hormone Therapy Tied to Blot Clots

• New Content on My Prostate Cancer Roadmap

• Doc Moyad’s “No Bogus Science” Column – “Statins & Risk of Fatal Prostate Cancer”

• Doctor Chodak’s Bottom Line

• Prostate RT and Risk of Rectal Cancer

• Read more..

Includes:

• MDV3100 in Prostate Cancer “Impressive”

• Bone Metastases Target of New Agent

• Benefits of Xgeva Don’t Outweigh Risks

• Medicare Will Continue Covering PSA Screening

• Finasteride Combo Reduces Recurring PSA

• Doc Moyad’s “No Bogus Science” Column – “Low-fat milk & Prostate Cancer Progression?”

• EBRT More Costly and Toxic than Other RT

• Us TOO Advocacy Issues Column

• Save the Dates for September Prostate Cancer Awareness Month

• Inherited Prostate Cancer Gene Identified

• Exercise Reduces Prostate Cancer Recurrence?

• Read more..

April   | View Newsletter

May   | View Newsletter

June   | View Newsletter

Includes:

• FDA Approves PCA3 Urine Test

• RP Improves Survival of PSA-Detected Cancer

• Men Opting for Costly New Cancer Treatment

• Robotic Vs. Open Radical Prostatectomy

• Finasteride and Dutasteride Do Not Control Low-Risk Prostate Cancer

• Result of the REDEEM Study of Dutasteride

• Us TOO Advocacy Issues

• Reduced Incidence of Post-Prostate Biopsy Infections by Using Rectal Swab Cultures

• Phase 3 Randomized Trial of Ipilimumab

• Ask Doctor Snuffy Myers

• Doc Moyad’s “No Bogus Science” Column – “Is it Time for Me to Start Drinking Coffee?”

• Doctor Chodak’s Bottom Line

• Read more..

Includes:

• Clinical Trials Deliver on the Promise of Science

• Early Access for MDV3100 and Alpharadin

• Serial Prostate Biopsies & Insignificant Cancers

• Prostate Cancer Misclassification by Current Low-Risk & Active Surveillance Criteria

• Association Between Smoking & PSA Levels

• Galeterone Safe & Effective in Prostate Cancer

• Oxygen in Tumors & Response to Radiotherapy

• Endorectal MRI & Active Surveillance

• Ask Doctor Snuffy Myers

• High-Dose Image Guided Radiotherapy Com-pared to IMRT for Localized Prostate Cancer

• Doc Moyad’s “No Bogus Science” Column – “The secret to long life is following 6-7 things”

• Gene Mapping Not a Crystal Ball if Healthy

• Doctor Chodak’s Bottom Line

• Read more..

Includes:

• Androgen Deprivation Therapy in Advanced Prostate Cancer Need Not Be Continuous

• Revised View Enhances Provenge Survival

• Avoiding Overtreatment of Prostate Cancer

• Iodine-125 or Palladium-103 Seeds Combined with External Beam Radiation Treatment?

• Prostate Cancer Cell Survival Factor Found

• New Erectile Dysfunction Drug Okayed by FDA

• Nutrition and Physical Activity Guidelines for Cancer Survivors

• Ask Doctor Snuffy Myers

• Doc Moyad’s “No Bogus Science” Column – “More Data Suggests Selenium is Not Safe”

• Doctor Chodak’s Bottom Line

• Read more..

July   | View Newsletter

August   | View Newsletter

September   | View Newsletter

Includes:

• Break from ADT Lowers Survival Odds

• Enzalutamide (MDV3100) is a Game Changer in Prostate Cancer

• Untreated Prostate Cancer Responds to Zytiga

• Postprostatectomy Test Identifies Risk for Clinical Recurrence

• Classifying Prostate Cancer by Quantitative Histomorphometry

• Prostate Cancer Screening Can Be Difference Between Life and Death for Some

• Pelvic Lymph Node Dissection in Prostate Cancer: Frequency and Nodal Distribution

• Ginseng Seems to Ease Cancer-Related Fatigue

• Doc Moyad’s “No Bogus Science” Column – “You Want a Real Cheap Anti-Aging Secret?”

• Doctor Chodak’s Bottom Line

• OGX-427 Improves Progression-Free Survival

• Read more..

Includes:

• Errors in USPSTF Report on PSA Testing

• Side Effects after Prostate Cancer Treatment

• Oncologists React to SCOTUS Ruling in ACA

• Spurious Elevation of Serum PSA after

• Curative Treatment for Prostate Cancer

• Hold Off On Radiation after Prostatectomy

• Meta-Analysis of Selenium-Prostate Cancer Link

• New FDA Approved Blood Test Improves Prostate Cancer Detection

• New Book by Dr. Snuffy Myers’ Prostate Forum

• Doc Moyad’s “No Bogus Science” Column –

• “Almonds to Lose Weight & Lower Cholesterol”

• Doctor Chodak’s Bottom Line

• Read more..

Includes:

• The Original Blues Brothers Band to Perform a Special Concert in Chicago to Benefit Us TOO

• PIVOT Results: Observation vs Prostatectomy

• Urine TMPRSS2:ERG Gene Fusion & PCA3

• Prevention of Gynecomastia due to ADT

• Active Surveillance Cost Same as Prostatectomy

• Go from Passion to Action in September

• More Men with Prostate Cancer Managed by A ‘Team’ Wait on Initiating Treatment

• OncoGenex Initiates Phase 3 “AFFINITY” Trial

• Doc Moyad’s “No Bogus Science” Column –“Vitamin D May Increase Testosterone? Maybe”

• Doctor Chodak’s Bottom Line

• Ask Dr. Snuffy Myers

• Thailand Military Bases & Agent Orange

• Read more..

October   | View Newsletter

November   | View Newsletter

December   | View Newsletter

Includes:

• FDA Approved XTANDI® (enzalutamide)

• Aspirin May Prolong Prostate Cancer Survival

• Provenge Immune Parameters Correlate with Survival in Castrate Resistant Patients

• Updated Partin Tables Using 2006-2011 Data

• Intermittent ADT for Post-RT PSA Recurrence

• Outcomes Using Active Surveillance in Men with Low Or Intermediate Risk Disease

• A “Way” to Resolve PSA Controversy

• Trial Comparing Laparoscopic and Robot-Assisted Radical Prostatectomy

• Accuracy of TRUSP-Guided 12-Core Biopsies

• Genes & Prostate Cancer in African Americans

• Doc Moyad’s “No Bogus Science” Column – “Testosterone Blood Test Should Be Fasting”

• Doctor Chodak’s Bottom Lin

• Read more..